Last reviewed · How we verify

NCT03276039

Serum Pentraxin-3 in Non-alcoholic Fatty Liver Disease With or Without Hepatitis C Virus

Completed Last updated 8 September 2017
What this trial tests

trial testing plasma pentraxin-3 in Non Alcoholic Fatty Liver Disease in 70 participants. Completed in 30 July 2016.

Timeline
15 April 2014
Primary endpoint
15 April 2016
30 July 2016

Quick facts

Lead sponsorAin Shams University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment70
Start date15 April 2014
Primary completion15 April 2016
Estimated completion30 July 2016

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Eligibility, any sex, with Non Alcoholic Fatty Liver Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study included 70 subjects divided into 3 groups. Group I included 25 patients with NAFLD. Group II included 25 patients with NAFLD and chronic HCV. Group III: included 20 controls. Abdominal ultrasound was done to patients and controls. Plasma pentraxin-3 (PTX3) was measured using ELISA. Comparison between three groups was done regarding plasma pentraxin-3. Higher levels of plasma PTX3 were detected in NAFLD patients irrespective of presence or absence of chronic HCV infection. Plasma PTX3 could be used as a non-invasive test for prediction of metabolic syndrome in the high-risk population with high sensitivity and moderate specificity.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Non Alcoholic Fatty Liver Disease

Currently open trials in the same condition.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03276039.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing